Birdshot Koryoretinopati ve Punktat İç Koroidit; Klinik, Tanı ve Tedavi

Birdshot koryoretinopati ve punktat iç koroidopati inflamatuar koryoretinopatilerin bir çeşidi ve beyaz nokta sendromlarının bir üyesidir. Bu hastalıkların tipik ve karakteristik görünümleri vardır. Bu hastalıklardaki lezyonlar retinanın birçok katını, retina pigment epitelini, koryokapillarisi ve koroidi etkiler. Bu derlemede bu hastalıkların etyolojilerini, klinik görünümlerini, tanılarını-ayırıcı tanılarını, tedavileri ve prognozlarını tartıştık.

Birdshot Chorioretinopathy and Punctate Inner Choroidopathy; Presentation, Diagnosis and Treatment

Birdshot chorioretinopathy and punctate inner choroidopathy are a form of inflammatory chorioretinopathies and a member of the white dot syndromes. These diseases have unique and characteristic appearances. The lesions in these diseases affect multiple layers of retina, retinal pigment epithelium, choriocapillaris and the choroid. We discuss the etiology, presentation, diagnosis-differential diagnosis, treatment and prognosis of these diseases in this review.


1. Abu-Yaghi NE, Hartono SP, Hodge DO, Pulido JS, Bakri S. White dot syndromes: a 20-year study of incidence, clinical features, and outcomes. Ocular Immunology and Inflammation. 2011;19:426–430.

2. Brown J, Folk JC, Reddy CV, Kimura AE. Visual prognosis of multifocal choroiditis, punctate inner choroidopathy, and the diffuse subretinal fibrosis syndrome. Ophthalmology. 1996;103:1100–1105.

3. Shah KH, Levinson RD, Yu F, Goldhardt R, Gordon LK, Gonzales CR, et al. Birdshot chorioretinopathy. Surv Ophthalmol. 2005;50(6):519–541.

4. Ünal M, Akbatur H. Kalıtsal olmayan ve nedeni bilinmeyen koryoretinopatiler. Oftalmoloji. 1993; 22:159-170.

5. Jones NP. The Manchester uveitis clinic: the first 3000 patients epidemiology and case mix. Ocul Immunol Inflamm. 2015;23(2):118–126.

6. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80(4):332–336.

7. Merrill PT, Kim J, Cox TA, Beto CC, McCallum RM, Jaffe GJ. Uveitis in the southeastern United States. Curr Eye Res. 1997;16:865–874.

8. Rodriguez A, Calonge M, Pedroza-Seres M, Akova YA, Messmer EM, D’Amico DJ, et al. Referral patterns of uveitis in a tertiary eye care center. Arch Ophthalmol. 1996;114:593–599.

9. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern Caifornia;the Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004;111(3):491–500.

10. Vadot E, Barth E, Billet P. Epidemiology of uveitis-preliminary results of a prospective study in Savoy. In: Saari K, editor. Uveitis update. Amsterdam: Elsevier; 1984. p. 13–6.

11. Minos, Barry RJ, Southworth S, Folkard A, Murray PI, Duker JS, et al. Birdshot chorioretinopathy: current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatment. Orphanet Journal of Rare Diseases. 2016;11:61.

12. Faia LJ. Gender differences in birdshot chorioretinopathy and the white dot syndromes: do they exist? J Ophthalmol. 2014;2014:146768.

13. LeHoang P, Ozdemir N, Benhamou A, Tabary T, Edelson C, Betuel H, et al. HLA-A29.2 subtype associated with birdshot retinochoroidopathy. Am J Ophthalmol. 1992;113(1):33–35.

14. Gasch AT, Smith JA, Whitcup SM. Birdshot retinochoroidopathy. Br J Ophthalmol. 1999;83:241–249.

15. Barondes MJ, Fastenberg DM, Schwartz PL, Rosen DA. Peripheral retinal neovascularization in birdshot retinochoroidopathy. Ann Ophthalmol. 1989;21:306–308.

16. Cao K, Hollenbach J, Shi X, Shi W, Chopek M, Fernández-Viña MA. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol. 2001;62(9):1009–1030.

17. Donvito B, Monnet D, Tabary T, Delair E, Vittier M, Réveil B, et al. Different HLA class IA region complotypes for HLA-A29.2 and -A29.1 antigens, identical in birdshot retinochoroidopathy patients or healthy individuals. Invest Ophthalmol Vis Sci. 2005;46:3227–3232.

18. Szpak Y, Vieville JC, Tabary T, Naud MC, Chopin M, Edelson C, et al. Spontaneous retinopathy in HLA-A29 transgenic mice. Proc Natl Acad Sci U S A. 2001;98(5):2572–6.

19. Gaudio PA, Kaye DB, Crawford JB. Histopathology of birdshot retinochoroidopathy. Br J Ophthalmol. 2002;86(12):1439–1441.

20. Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporine therapy in the treatment of birdshot retinochoroidopathy. Ophthalmology. 1994;101(5):822–831

21. Granados DP, Yahyaoui W, Laumont CM, Daouda T, Muratore-Schroeder TL, Côté C, et al. MHC I-associated peptides preferentially derive from transcripts bearing miRNA response elements. Blood. 2012;119(26):181– 191.

22. Kuiper J, Rothova A, de Boer J, Radstake T. The immunopathogenesis of birdshot chorioretinopathy; a bird of many feathers. Prog Retin Eye Res. 2015; 44:99-110.

23. Kuiper JJ, Mutis T, de Jager W, de Groot-Mijnes JD, Rothova A. Intraocular interleukin-17 and proinflammatory cytokines in HLA-A29-associated birdshot chorioretinopathy. Am J Ophthalmol. 2011;152(2): 177–182.

24. Yang P, Foster CS. Interleukin 21, interleukin 23, and transforming growth factor beta1 in HLA-A29-associated birdshot retinochoroidopathy. Am J Ophthalmol. 2013;156(2):400–406.

25. Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Melissa Liew SH, Beziyak V, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120(4):777–787.

26. Keane PA, Allie M, Turner SJ, Southworth HS, Sadda SR, Murray PI, et al. Characterization of birdshot chorioretinopathy using extramacular enhanced depth optical coherence tomography. JAMA Ophthalmol. 2013;131(3):341–350.

27. Rothova A, Berendschot TT, Probst K, van Kooij B, Baarsma GS. Birdshot chorioretinopathy: long term manifestations and visual prognosis. Ophthalmology. 2004;111(5):954–959.

28. Levinson RD, Monnet D, Yu F, Holland GN, Gutierrez P, Brezin AP. Longitudinal cohort study of patients with birdshot chorioretinopathy. V. Quality of life at baseline. Am J Ophthalmol. 2009;147(2): 346–350.

29. Donvito B, Monnet D, Tabary T, Delair E, Vittier M, Réveil B, et al. A new HLA extended haplotype containing the A*2910 allele in birdshot reti-nochoroidopathy: Susceptibility narrowed to the HLA molecule itself. Invest Ophthalmol Vis Sci. 2010; 51: 2525-2528.

30. Priem HA, Oosterhuis JA. Birdshot chorioretinopathy: clinical characteristics and evolution. Br J Ophthalmol. 1988;72(9):646–659.

31. Gelişken Ö. Pars planit ve birdshot koryoretinopati. XXV Ulusal Türk Oftalmoloji Kongresi Bülteni. 1991;1:119-123.

32. Godel V, Baruch E, Lazar M. Late development of chorioretinal lesions in birdshot retinochoroidopathy. Ann Ophthalmol. 1989;21(2):49–52.

33. Levinson RD, Brézin A, Rothova A, Accorinti M, Holland GN. Research criteria for the diagnosis of birdshot chorioretinopathy: results of an international consensus conference. Am J Ophthalmol. 2006;141(1):185– 187.

34. Hesse S, Berbis P, Chemila JF, Privat Y. Psoriasis and birdshot chorioretinopathy: response to aromatic retinoids. Dermatology. 1993;187(2):137– 139.

35. Zamecki KJ, Jabs DA. HLA typing in uveitis: use and misuse. Am J Ophthalmol. 2010;149:189–193.

36. Atmaca LS, Atilla H, Batıoğlu F. Üveitlerde flöresein anjiyografi. MN Oftalmoloji. 1994;1:225-235.

37. Guex-Crosier Y, Herbort CP. Prolonged retinal arteriovenous circulation time by fluorescein but not by indocyanine green angiography in birdshot chorioretinopathy. Ocul Immunol Inflamm. 1997;5:203–206.

38. Fardeau C, Herbort CP, Kullmann N, Quentel G, LeHoang P. Indocyanine green angiography in birdshot chorioretinopathy. Ophthalmology. 1999; 106:1928–1934.

39. Herbort CP, Probst K, Cimino L, Tran VT. Differential inflammatory involvement in retina and choroid in birdshot chorioretinopathy. Klin Monbl Augenheilkd. 2004;221:351–356.

40. Birch DG, Williams PD, Callanan D, Wang R, Locke KG, Hood DC. Macular atrophy in birdshot retinochoroidopathy: an optical coherence tomography and multifocal electroretinography analysis. Retina. 2010;30:930–937.

41. Forooghian F, Yeh S, Faia LJ, Nussenblatt RB. Uveitic foveal atrophy: clinical features and associations. Arch Ophthalmol. 2009;127:179–186.

42. Birnbaum AD, Fawzi AA, Rademaker A, Goldstein DA. Correlation between clinical signs and optical coherence tomography with enhanced depth imaging findings in patients with birdshot chorioretinopathy. JAMA Ophthalmol. 2014;132(8):929–935.

43. Skvortsova N, Gasc A, Jeannin B, Herbort CP. Evolution of choroidal thickness over time and effect of early and sustained therapy in birdshot retinochoroiditis. Eye (Lond). 2017;31(8):1205-1211.

44. de Carlo TE, Bonini-Filho MA, Adhi M, Duker JS. Retinal and choroidal. Vasculature in birdshot chorioretinopathy analyzed using spectral domain optical coherence tomography angiography. Retina. 2015;35(11):2392– 9239.

45. Pohlmann D, Macedo S, Stübiger N, Pleyer U, Joussen AM, Winterhalter S. Multimodal Imaging in Birdshot Retinochoroiditis. Ocul Immunol Inflamm. 2017;25(5):621-632.

46. Roberts PK, Nesper PL, Goldstein DA, Fawzi AA. Retinal capillary density in patients with birdshotchorioretinopathy. Retina. 2018;38(2):387- 394.

47. Koizumi H, Pozzoni MC, Spaide RF. Fundus autofluorescence in birdshot chorioretinopathy. Ophthalmology. 2008;146(4):496–500.

48. Böni C, Thorne JE, Spaide RF, Ostheimer TA, Sarraf D, Levinson RD,et al Fundus Autofluorescence Findings in Eyes With Birdshot Chorioretinitis. Invest Ophthalmol Vis Sci. 2017;58(10):4015-4025.

49. Sobrin L, Lam BL, Liu M, Feuer WJ, Davis JL. Electroretinographic monitoring in birdshot chorioretinopathy. Am J Ophthalmol. 2005;140:52–64.

50. Zacks DN, Samson CM, Loewenstein J, Foster CS. Electroretinograms as an indicator of disease activity in birdshot retinochoroidopathy. Graefes Arch Clin Exp Ophthalmol. 2002;240:601–607.

51. Holder GE, Robson AG, Pavesio C, Graham EM. Electrophysiological characterisation and monitoring in the management of birdshot chorioretinopathy. Br J Ophthalmol. 2005;89:709–718.

52. Moschos MM, Gouliopoulos NS, Kalogeropoulos C. Electrophysiological examination in uveitis: a review of the literature. Clin Ophthalmol. 2014;8:199–214.

53. Hirose T, Katsumi O, Pruett RC, Sakaue H, Mehta M. Retinal function in birdshot retinochoroidopathy. Acta Ophthalmol Copenh. 1991;69:327– 337.

54. Comander J, Loewenstein J, Sobrin L. Diagnostic testing and disease monitoring in birdshot chorioretinopathy. Semin Ophthalmol. 2011;26(4– 5):329–336.

55. Mailhac A, Labarere J, Aptel F, Berthemy S, Bouillet L, Chiquet C. Five-Year Trends in Multifocal Electroretinogram for Patients With Birdshot Chorioretinopathy. Am J Ophthalmol. 2019;200:138-149.

56. Gordon LK, Goldhardt R, Holland GN, Yu F, Levinson RD. Standardized visual field assessment for patients with birdshot chorioretinopathy. Ocul Immunol Inflamm. 2006;14(6):325–332.

57. Thorne JE, Jabs DA, Kedhar SR, Peters GB, Dunn JP. Loss of visual field among patients with birdshot chorioretinopathy. Am J Ophthalmol. 2008; 145(1):23–28.

58. Becker MD, Wertheim MS, Smith JR, Rosenbaum JT. Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppression. Ocul Immunol Inflamm. 2005;13:289–293.

59. Oh KT, Christmas NJ, Folk JC. Birdshot retinochoroiditis: long term follow-up of a chronically progressive disease. Am J Ophthalmol. 2002;133:622–629.

60. Read RW, Rao NA, Sharma OP. Sarcoid choroiditis initially diagnosed as birdshot choroidopathy. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17:85– 86.

61. Miserocchi E, Modorati G, De Benedetto U, Colucci A, Bandello F. Birdshot retinochoroidopathy masquerading as intraocular lymphoma. Ocul Immunol Inflamm. 2012;20(4):306–308.

62. Willermain F, Greiner K, Forrester JV. Atypical end-stage birdshot retinochoroidopathy. Ocul Immunol Inflamm. 2003;11:305–307.

63. Ryan SJ, Maumenee AE. Acute posterior multifocal placoid pigment epitheliopathy. Am J Ophthalmol. 1972;74:1066–1074.

64. Gass JD. Acute posterior multifocal placoid pigment epitheliopathy. Arch Ophthalmol. 1968;80:177–185.

65. Dreyer RF, Gass DJ. Multifocal choroiditis and panuveitis. A syndrome that mimics ocular histoplasmosis. Arch Ophthalmol. 1984;102:1776– 1784.

66. Kiss S, Ahmed M, Letko E, Foster CS. Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalmology. 2005;112(6):1066–1071.

67. Lages V, Skvortsova N, Jeannin B, Gasc A, Herbort CP. Low-grade “benign” birdshot retinochoroiditis: prevalence and characteristics. Int Ophthalmol. 2018 Nov 24. [Epub ahead of print]

68. Doycheva D, Jägle H, Zierhut M, Deuter C, Blumenstock G, Schiefer U, et al. Mycophenolic acid in the treatment of birdshot chorioretinopathy: long-term follow-up. Br J Ophthalmol. 2015;99(1):87–91.

69. Tomkins-Netzer O, Taylor SR, Lightman S. Longterm clinical and anatomic outcome of birdshot chorioretinopathy. JAMA Ophthalmol. 2014;132(1):57–62.

70. Cervantes-Castañeda RA, Gonzalez LA, Cordero-Coma M, Yilmaz T, Foster CS. Combined therapy of cyclosporine A and mycophenolate mofetil for the treatment of birdshot retinochoroidopathy: a 12 month follow up. Br J Ophthalmol. 2013;97(5):637–643.

71. Rothova A, Ossewaarde-van Norel A, Los LI, Berendschot TT. Efficacy of low-dose methotrexate treatment in birdshot chorioretinopathy. Retina. 2011;131(6):1150–1155.

72. Vitale AT, Rodriguez A, Foster CS. Low dose cyclosporine therapy in the treatment of birdshot retinochoroidopathy. Ophthalmology. 1994; 101:822–831.

73. Le Hoang P, Girard B, Deray G, Le Minh H, De Kozak Y, Thillaye B, et al. Cyclosporine in the treatment of birdshot retinochoroidopathy. Transplant Proc. 1988;20:128–130.

74. Artornsombudh P, Gevorgyan O, Payal A, Siddique SS, Foster CS. Infliximab treatment of patients with birdshot retinochoroidopathy. Ophthalmology. 2013;120(3):588–592.

75. Mesquida M, Molins B, Llorenç V, Sainz de la Maza M, Adán A. Longterm effects of tocilizumab therapy for refractory uveitis-related macular edema. Ophthalmology. 2014;121(12):2380–2386.

76. Leclercq M, Le Besnerais M, Langlois V, Girszyn N, Benhamou Y, Ngo C, et al. Tocilizumab for the treatment of birdshot uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy: two cases report and literature review. Clin Rheumatol. 2018;37(3):849-853.

77. Sobrin L, Huang JJ, Christen W, Kafkala C, Choopong P, Foster CS. Daclizumab for treatment of birdshot chorioretinopathy. Arch Ophthalmol. 2008;126(2):186–191.

78. Yeh S, Wroblewski K, Buggage R, Li Z, Kurup SK, Sen HN, et al. High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. Br J Ophthalmol. 2018;102(7):983- 990.

79. Islam F, Westcott M, Rees A, Robson AG, Kapoor B, Holder G, et al. Safety profile and efficacy of tacrolimus in the treatment of birdshotretinochoroiditis: a retrospective case series review. Br J Ophthalmol. 2018;102(7):983-990.

80. Huis Het Veld PI, van Asten F, Kuijpers RWAM, Rothova A, de Jong EK, Hoyng CB. Adalimumab therapy for refractory birdshotchorioretinopathy. Retina. 2018 Jul 31. [Epub ahead of print]

81. Steeples LR, Spry P, Lee RWJ, Carreño E. Adalimumab in refractory cystoid macular edema associated with birdshot chorioretinopathy. Int Ophthalmol. 2018;38(3):1357-1362.

82. Cassoux N, Goichot-Bonnat L, Karmochkine M, Georges F, Kullmann N, Lehoang P, et al. Efficacy of intravenous immunoglobulin in the treatment of Birdshot retinochoroiditis. J Fr Ophtalmol. 2002;25(1):23–30.

83. Bodaghi B, Gendron G, Wechsler B, Terrada C, Cassoux N, Huong du LT,et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol. 2007;91(3): 335–339.

84. Thorne JE, Jabs DA, Peters GB, Hair D, Dunn JP, Kempen JH. Birdshot retinochoroidopathy: ocular complications and visual impairment. Am J Ophthalmol. 2005;140(1):45–51.

85. Bajwa A, Peck T, Reddy AK, Netland PA, Shildkrot Y. Dexamethasone implantation in birdshot chorioretinopathy - long-term outcome. Int Med Case Rep J. 2018;11:349-358.

86. Rivera de Zea P, García-Ben A, Rachwani Parshotam N, García-Campos JM. Dexamethasone intravitreal implant for treatment of persistent macular oedema in Birdshot retinochoroidopathy. Arch Soc Esp Oftalmol. 2016;91(3):138-141.

87. Moisseiev E, Moshiri A. Ozurdex for the Treatment of a Patient with Birdshot Chorioretinopathy. Case Rep Ophthalmol. 2015;6(3):289–292.

88. Yap YC, Papathomas T, Kamal A. Results of intravitreal dexamethasone implant 0.7 mg (Ozurdex®) in non-infectious posterior uveitis. Int J Ophthalmol. 2015;8(4):835–838.

89. Zarranz-Ventura J, Carreño E, Johnston RL, Mohammed Q, Ross AH, Barker C, et al. Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency. Am J Ophthalmol. 2014;158(6):1136–1145.

90. Pelegrín L, de la Maza MS, Molins B, Ríos J, Adán A. Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to noninfectious uveitis. Eye (Lond). 2015;29(7):943–950.

91. Mackensen F, Heinz C, Becker MD, Heiligenhaus A. Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina. 2008;28(1):41–45.

92. Weiss K, Steinbrugger I, Weger M, Ardjomand N, Maier R, Wegscheider BJ, et al. Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab. Eye (Lond). 2009;23(9):1812–1818.

93. Watzke RC, Packer AJ, Folk JC, Benson WE, Burgess D, Ober RR. Punctate inner choroidopathy. Am J Ophthalmol. 1984;98(5):572-584.

94. Ahnood D, Madhusudhan S, Tsaloumas MD, Waheed NK, Keane PA, Denniston AK. Punctate inner choroidopathy: A review. Surv Ophthalmol. 2017;62(2):113-126.

95. Channa R, Ibrahim M, Sepah Y, Turkcuoglu P, Lee JH, Khwaja A, et al. Characterization of macular lesions in punctate inner choroidopathy with spectral domain optical coherence tomography. J Ophthalmic Inflamm Infect. 2012;2(3):113-120.

96. Brown J Jr, Folk JC, Reddy CV, Kimura AE. Visual prognosis of multifocal choroiditis, punctate inner choroidopathy, and the diffuse subretinal fibrosis syndrome. Ophthalmology. 1996;103(7):1100-1105.

97. Jones NP. The Manchester Uveitis Clinic: the first 3000 patientsdepidemiology and casemix. Ocul Immunol Inflamm. 2015;23(2):118-126.

98. Gerstenblith AT, Thorne JE, Sobrin L, Do DV, Shah SM, Foster CS, et al. Punctate inner choroidopathy: a survey analysis of 77 persons. Ophthalmology. 2007;114(6):1201-1204.

99. Patel KH, Birnbaum AD, Tessler HH, Goldstein DA. Presentation and outcome of patients with punctate inner choroidopathy at a tertiary referral center. Retina. 2011;31(7):1387-1391.

100. Niederer RL, Gilbert R, Lightman SL, Tomkins-Netzer O. Risk Factors for Developing Choroidal Neovascular Membrane and Visual Loss in Punctate Inner Choroidopathy.Ophthalmology. 2018;125(2):288-294.

101. Essex RW, Wong J, Fraser-Bell S, Sandbach J, Tufail A, Bird AC, et al. Punctate inner choroidopathy: clinical features and outcomes. Arch Ophthalmol. 2010;128(8):982-987.

102. Reddy CV, Brown J Jr, Folk JC, Kimura AE, Gupta S, Walker J. Enlarged blind spots in chorioretinal inflammatory disorders. Ophthalmology. 1996;103(4):606-617.

103. Jampol LM, Becker KG. White spot syndromes of the retina: a hypothesis based on the common genetic hypothesis of autoimmune/inflammatory disease. Am J Ophthalmol. 2003;135(3):376-379.

104. Atan D, Fraser-Bell S, Plskova J, Kuffová L, Hogan A, Tufail A, et al. Punctate inner choroidopathy and multifocal choroiditis with panuveitis share haplotypic associations with IL10 and TNF loci. Invest Ophthalmol Vis Sci. 2011;52(6):3573-3581.

105. Sugawara E, Machida S, Fujiwara T, Kurosaka D, Hayakawa M. Punctate inner choroidopathy in mother and daughter. Jpn J Ophthalmol. 2010;54(5):505-507.

106. Olsen TW, Capone A Jr, Sternberg P Jr, Grossniklaus HE, Martin DF, Aaberg TM Sr. Subfoveal choroidal neovascularization in punctate inner choroidopathy. Surgical management and pathologic findings. Ophthalmology. 1996;103(12):2061-2069.

107. Shimada H, Yuzawa M, Hirose T, Nakashizuka H, Hattori T, Kazato Y. Pathological findings of multifocal choroiditis with panuveitis and punctate inner choroidopathy. Jpn J Ophthalmol. 2008;52(4):282-288.

108. Zhang X, Zuo C, Li M, Chen H, Huang S, Wen F. Spectral domain optical coherence tomographic findings at each stage of punctate inner choroidopathy. Ophthalmology. 2013;120(12):2678-2683.

109. Hirooka K, Saito W, Hashimoto Y, Saito M, Ishida S. Increased macular choroidal blood flow velocity and decreased choroidal thickness with regression of punctate inner choroidopathy. BMC Ophthalmol. 2014;14:73.

110. Channa R, Ibrahim M, Sepah Y, Turkcuoglu P, Lee JH, Khwaja A, et al. Characterization of macular lesions in punctate inner choroidopathy with spectral domain optical coherence tomography. J Ophthalmic Inflamm Infect. 2012;2(3):113-20.

111. Amer R, Lois N. Punctate inner choroidopathy. Surv Ophthalmol. 2011;56(1):36-53.

112. Essex RW, Tufail A, Bunce C, Aylward GW. Two-year results of surgical removal of choroidal neovascular membranes related to non-age-related macular degeneration. Br J Ophthalmol. 2007;91(5):649-654.

113. Leung AK, Weisbrod DJ, Schwartz C. Intravitreal ranibizumab in the treatment of choroidal neovascular membrane secondary to punctate inner choroidopathy. Can J Ophthalmol. 2010;45(3):300-301.

114. Buerk BM, Rabb MF, Jampol LM. Peripapillary subretinal fibrosis: a characteristic finding of multifocal choroiditis and panuveitis. Retina. 2005;25(2):228-229.

115. Baxter SL, Pistilli M, Pujari SS, Liesegang TL, Suhler EB, Thorne JE, et al. Risk of choroidal neovascularization among the uveitides. Am J Ophthalmol. 2013;156(3):468-477.

116. Levy J, Shneck M, Klemperer I, Lifshitz T. Punctate inner choroidopathy: resolution after oral steroid treatment and review of the literature. Can J Ophthalmol. 2005;40(5):605-608.

117. Tiffin PA, Maini R, Roxburgh ST, Ellingford A. Indocyanine green angiography in a case of punctate inner choroidopathy. Br J Ophthalmol. 1996;80(1):90-91.

118. Zhang X,WenF, Zuo C, Li M, Chen H, Huang S,et al. Clinical features of punctate inner choroidopathy in Chinese patients. Retina. 2011;31(8):1680-91.

119. Ciulla TA, Piper HC, Xiao M, Wheat LJ. Presumed ocular histoplasmosis syndrome: update on epidemiology, pathogenesis, and photodynamic, antiangiogenic, and surgical therapies. Curr Opin Ophthalmol. 2001;12(6):442-449.

120. Kim H, Woo SJ, Kim YK, Lee SC, Lee CS. Focal choroidal excavation in multifocal choroiditis and punctate inner choroidopathy. Ophthalmology. 2015;122(7):1534-1535.

121. Spaide RF, Goldberg N, Freund KB. Redefining multifocal choroiditis and panuveitis and punctate inner choroidopathy through multimodal imaging. Retina. 2013;33(7):1315-1324.

122. Klufas MA, O’Hearn T, Sarraf D. Optical coherence tomography angiography and widefield fundus autofluorescence in punctate inner choroidopathy. Retin Cases Brief Rep. 2015;9(4):323-326.

123. Levison AL, Baynes KM, Lowder CY, Kaiser PK, Srivastava SK. Choroidal neovascularization on optical coherence tomography angiography in punctate inner choroidopathy and multifocal choroiditis. Br J Ophthalmol 2017;101(5):616-622..

124. Zarranz-Ventura J, Sim DA, Keane PA, Patel PJ, Westcott MC, Lee RW, et al. Characterization of punctate inner choroidopathy using enhanced depth imaging optical coherence tomography. Ophthalmology. 2014;121(9):1790-1797.

125. Valverde Megı´as A, Arriola Villalobos P, Reche Frutos J, Donate Lo´pez J, Calvo Gonza´ lez C, Garcı´a Feijoo J. Intravitreal ranibizumab (Lucentis) in the treatment of choroidal neovascular membrane secondary to punctate inner choroidopathy. Arch Soc Esp Oftalmol. 2010;85(4):149- 152.

126. Madhusudhan S, Keane PA, Denniston AK. Adjunctive use of systematic retinal thickness map analysis to monitor disease activity in punctate inner choroidopathy. J Ophthalmic Inflamm Infect. 2016;6(1):9.

127. Li M, Zhang X, Wen F. The fundus autofluorescence spectrum of punctate inner choroidopathy. J Ophthalmol. 2015;2015:202097.

128. Munk MR, Jung JJ, Biggee K, Tucker WR, Sen HN, Schmidt-Erfurth U, et al. Idiopathic multifocal choroiditis/punctate inner choroidopathy with acute photoreceptor loss or dysfunction out of proportion to clinically visible lesions. Retina. 2015;35(2):334-343.

129. Hua R, Liu L, Chen L. Evaluation of the progression rate of atrophy lesions in punctate inner choroidopathy (PIC) based on autofluorescence analysis. Photodiagnosis Photodyn Ther. 2014;11(4):565-569.

130. Essex RW, Wong J, Jampol LM, Dowler J, Bird AC. Idiopathic multifocal choroiditis: a comment on present and past nomenclature. Retina. 2013;33(1):1-4.

131. Kedhar SR, Thorne JE, Wittenberg S, Dunn JP, Jabs DA. Multifocal choroiditis with panuveitis and punctate inner choroidopathy: comparison of clinical characteristics at presentation. Retina. 2007;27(9):1174-1179.

132. Prasad AG, Van Gelder RN. Presumed ocular histoplasmosis syndrome. Curr Opin Ophthalmol. 2005;16(6):364-368.

133. Kaiser OK, Gragoudas HY. The subretinal fibrosis and uveitis syndrome. Int Ophthalmol Clin. 1996;36(1):145-152.

134. Ryan SJ, Maumenee AE. Acute posterior multifocal placoid pigment epitheliopathy. Am J Ophthalmol. 1972;74(6):1066-1074.

135. Barile GR, Reppucci VS, Schiff WM, Wong DT. Circumpapillary chorioretinopathy in multiple evanescent white-dot syndrome. Retina. 1997;17(1):75-77.

136. Matsuda S, Gomi F, Oshima Y, Tohyama M, Tano Y. Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress. Invest Ophthalmol Vis Sci. 2005;46(3):1062-8.

137. Brueggeman RM, Noffke AS, Jampol LM. Resolution of punctate inner choroidopathy lesions with oral prednisone therapy. Arch Ophthalmol. 2002;120(7):996.

138. Flaxel CJ, Owens SL, Mulholland B, Schwartz SD, Gregor ZJ. The use of corticosteroids for choroidal neovascularization in young patients. Eye (Lond). 1998;12:266-272.

139. Turkcuoglu P, Chang PY, Rentiya ZS, Channa R, Ibrahim M, Hatef E, et al. Mycophenolate mofetil and fundus autofluorescence in the management of recurrent punctate inner choroidopathy. Ocul Immunol Inflamm. 2011;19(4):286-292.

140. Nussenblatt RB, Coleman H, Jirawuthiworavong G, Davuluri G, Potapova N, Dahr SS, et al. The treatment of multifocal choroiditis associated choroidal neovascularization with sirolimus (rapamycin). Acta Ophthalmol Scand. 2007;85(2):230-231.

141. Cirino AC, Mathura JR Jr, Jampol LM. Resolution of activity (choroiditis and choroidal neovascularization) of chronic recurrent punctate inner choroidopathy after treatment with interferon B-1A. Retina. 2006;26(9):1091-1092.

142. Mansour AM, Arevalo JF, Ziemssen F, Mehio-Sibai A, Mackensen F, Adan A, et al. Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol. 2009;148(2):310-316.

143. Cornish KS, Williams GJ, Gavin MP, Imrie FR. Visual and optical coherence tomography outcomes of intravitreal bevacizumab and ranibizumab in inflammatory choroidal neovascularization secondary to punctate inner choroidopathy. Eur J Ophthalmol. 2011;21(4):440-445.

144. Zhang H, Liu ZL, Sun P, Gu F. Intravitreal bevacizumab as primary treatment of choroidal neovascularization secondary to punctate inner choroidopathy: results of a 1-year prospective trial. Retina. 2012;32(6):1106- 1113.

145. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol. 2007;143(6):977-983.

146. Rouvas A, Petrou P, Douvali M, Ntouraki A, Vergados I, Georgalas I, et al. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization. Retina. 2011;31(5):871-879.

147. Pachydaki SI, Jakobiec FA, Bhat P, Sobrin L, Michaud NA, Seshan SV, et al. Surgical management and ultrastructural study of choroidal neovascularization in punctate inner choroidopathy after bevacizumab. J Ophthalmic Inflamm Infect. 2012;2(1):29-37.

148. Tsaousis KT, Nassr M, Kapoor B, Konidaris VE, Tyradellis S, Empeslidis T. Long-term results of intravitreal bevacizumab and dexamethasone for the treatment of punctate inner choroidopathy associated with choroidal neovascularization: A case series. SAGE Open Med Case Rep. 2018;6:2050313X18772478.

149. Wu W, Li S, Xu H, Liu Y, Wang Y, Lai TYY, Yin ZQ. Treatment of punctate ınner choroidopathy with choroidal neovascularization using corticosteroid and intravitreal ranibizumab. Biomed Res Int. 2018;2018:1585803.

150. Arrevola L, Acero MA, Peral MJ. Two-Year Outcome of Aflibercept for the Treatment of Choroidal Neovascularization in Punctate Inner Choroidopathy. Case Rep Ophthalmol. 2019;10(1):24-31.

151. Coco RM, de Souza CF, Sanabria MR. Photodynamic therapy for subfoveal and juxtafoveal choroidal neovascularization associated with punctate inner choroidopathy. Ocul Immunol Inflamm. 2007;15(1):27-29.

152. Leslie T, Lois N, Christopoulou D, Olson JA, Forrester JV. Photodynamic therapy for inflammatory choroidal neovascularization unresponsive to immunosuppression. Br J Ophthalmol. 2005;89(2):147-150.

153. Rogers AH, Duker JS, Nichols N, Baker BJ. Photodynamic therapy of idiopathic and inflammatory choroidal neovascularization in young adults. Ophthalmology. 2003;110(7):1315-1320.

154. Chan WM, Lai TY, Lau TT, Lee VY, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone for choroidal neovascularization secondary to punctate inner choroidopathy or of idiopathic origin: one-year results of a prospective series. Retina. 2008;28(1):71-80.

155. Fong KC, Thomas D, Amin K, Inzerillo D, Horgan SE. Photodynamic therapy combined with systemic corticosteroids for choroidal neovascularization secondary to punctate inner choroidopathy. Eye (Lond). 2008;22(4):528-533.

Kaynak Göster